Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

NeoRx Corp.

(NERX)

Business: Drug delivery/imaging

Peter Ginsberg of Vector Securities

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE